Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis.

Dapagliflozin: A Powerful Drug with a Rare but Serious Side Effect

The world of [diabetes management] has seen significant advancements in recent years, with new drug classes emerging to improve glycemic control. This research delves into the rare but potentially serious side effect of euglycemic diabetic ketoacidosis (eDKA) associated with the use of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor.

The authors present a case report of a patient who developed late-onset eDKA after stopping dapagliflozin. This case is particularly intriguing because the patient had already stopped taking the medication two weeks before experiencing the symptoms. The authors highlight the challenges in diagnosing eDKA, particularly due to near-normal glucose levels.

A Rare But Serious Side Effect

The research underscores the importance of recognizing the potential for eDKA, even when patients have stopped taking dapagliflozin. Healthcare providers need to be aware of the delayed onset of this side effect and remain vigilant in monitoring patients who have been prescribed SGLT2 inhibitors.

Ensuring Patient Safety

This research highlights the importance of careful patient selection and monitoring when prescribing SGLT2 inhibitors. Understanding the potential for eDKA and recognizing its symptoms are critical for ensuring patient safety.

Dr.Camel's Conclusion

The journey of managing diabetes requires a delicate balance between treatment benefits and potential risks. This research serves as a reminder that even seemingly safe drugs can have rare but serious side effects. Like a wise camel navigating the shifting sands of the desert, healthcare providers must remain vigilant in monitoring their patients and adjusting treatment plans accordingly.